CRMD Sep 2024 5.000 call
| Previous Close | 1.1400 |
| Open | 1.1400 |
| Bid | 1.0000 |
| Ask | 1.3500 |
| Strike | 5.00 |
| Expire Date | 2024-09-20 |
| Day's Range | 1.1400 - 1.1400 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 2k |
Insider MonkeyCorMedix Inc. (NASDAQ:CRMD) Q1 2024 Earnings Call Transcript
CorMedix Inc. (NASDAQ:CRMD) Q1 2024 Earnings Call Transcript May 11, 2024 CorMedix Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to the CorMedix First Quarter 2024 Earnings Conference Call [Operator Instructions]. Today’s conference call is […]
GlobeNewswireCorMedix Inc. to Participate in Two Upcoming Investor Conferences
BERKELEY HEIGHTS, N.J., May 10, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that management will be participating in fireside chats and investor meetings at both the JMP Securities Life Sciences Conference being held in New York on May 13 – 14, 2024 and the 2024 RBC Capital Markets Global Healthcare Conference being held in New York o
- GlobeNewswire
CorMedix Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Conference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the first quarter ended March 31, 2024 and provided an update on its business. Recent Corporate Highlights: On April 2, 2024, CMS published its HCPCS coding decision for DefenCa
